Chemistry Wealth Management Increases UnitedHealth Group Stake by 59.2% to 16,199 Shares
Chemistry Wealth Management LLC increased its UnitedHealth Group stake by 59.2% to 16,199 shares in Q3, purchasing an extra 6,022 shares. The position, valued at $5.593 million, accounted for 1.1% of the fund’s portfolio, making UnitedHealth Group its 18th largest holding.
1. Chemistry Wealth Management Raises Stake
Chemistry Wealth Management LLC increased its position in UnitedHealth Group by 59.2% during the third quarter, acquiring an additional 6,022 shares to bring its total to 16,199. This holding represents approximately 1.1% of the firm’s overall portfolio and ranks as its 18th largest position. At the end of the reporting period, the value of the stake stood at $5,593,000, marking a significant confidence vote in the healthcare conglomerate’s long-term prospects.
2. Institutional Investor Movements
Several other major institutional investors also made sizeable moves in UnitedHealth Group during the second quarter. Norges Bank initiated a new position valued at $3.84 billion, while Berkshire Hathaway added a $1.57 billion stake. Dodge & Cox more than doubled its exposure, increasing its share count by 117.7% to 8.75 million shares (worth $2.73 billion), and Amundi raised its position by 33.8% to 6.19 million shares (valued at $1.90 billion). Overall, 87.86% of UnitedHealth Group’s stock is held by institutional investors, underscoring the company’s appeal among large asset managers.
3. Analyst Ratings and Targets
Wall Street firms have recently revised their outlook on UnitedHealth Group. Morgan Stanley upgraded to an overweight rating and lifted its price target from $325 to $395. Royal Bank of Canada moved to an outperform rating with a revised target of $408, and UBS raised its objective to $430 while maintaining a buy recommendation. Goldman Sachs initiated coverage with a buy rating and a $406 target, and Zacks Research shifted from strong sell to hold. Among seventeen buy, nine hold and three sell ratings, the consensus target sits at $385.54, reflecting a balanced view on near-term valuation and growth potential.
4. Recent Financial Performance and Dividend
In its latest quarterly report, UnitedHealth Group delivered earnings per share of $2.92, surpassing consensus estimates by $0.05, on revenue of $113.16 billion, up 12.2% year-over-year. The company reported a net margin of 4.04% and a return on equity of 19.23%. Balance‐sheet metrics remained solid, with a debt‐to‐equity ratio of 0.71 and current and quick ratios of 0.82. The board declared a quarterly dividend of $2.21 per share, equating to an $8.84 annual payout and a 2.7% yield, supported by a payout ratio of 46.14%.